Suppr超能文献

手术微波消融治疗肝细胞癌的 10 年实际生存率:日本单中心经验。

Actual 10-Year Survival After Surgical Microwave Ablation for Hepatocellular Carcinoma: A Single-Center Experience in Japan.

机构信息

Department of Hepato-Biliary-Pancreatic Surgery, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.

出版信息

Ann Surg Oncol. 2019 Nov;26(12):4126-4133. doi: 10.1245/s10434-019-07646-8. Epub 2019 Jul 29.

Abstract

BACKGROUND

Little evidence exists regarding long-term survival after microwave ablation for hepatocellular carcinoma (HCC). The aim of this study is to determine actual 10-year survival and clarify the clinicopathological features of patients surviving ≥ 10 years after surgical microwave ablation.

PATIENTS AND METHODS

This retrospective study identified 459 patients who underwent surgical microwave ablation for HCC with curative intent between 2001 and 2008. We compared 100 patients who survived ≥ 10 years with 321 patients who died within 10 years.

RESULTS

Median overall survival and recurrence-free survival rates were 5.5 and 2.4 years, respectively. The actual 10-year overall survival rate was 23.8%, and the actual 10-year recurrence-free survival rate was 8.1%. Multivariate analysis showed that age > 70 years [odds ratio 1.87, P = 0.029], hepatitis C virus positivity (OR 2.30, P = 0.004), Child-Pugh class B (OR 3.28, P = 0.003), and platelet count < 10 × 10 /µL (OR 1.93, P = 0.033) were independent risk factors for actual 10-year survival. During 10-year follow-up, 66% of the ≥ 10-year survivors developed recurrence, and 91% of these patients underwent further curative treatment, including hepatic resection or local ablation, for HCC recurrence.

CONCLUSION

Ten-year survival after surgical microwave ablation for HCC can be expected in approximately 24% of patients, even though nearly 2/3 of our 10-year survival patients experienced recurrence. Close postoperative follow-up and further curative treatment for recurrence are important for improving long-term survival.

摘要

背景

关于肝癌(HCC)微波消融治疗后的长期生存情况,证据有限。本研究旨在确定实际的 10 年生存率,并阐明 10 年以上生存患者的临床病理特征。

患者和方法

本回顾性研究纳入了 2001 年至 2008 年间因 HCC 接受手术微波消融治疗且具有治愈意向的 459 例患者。我们比较了 100 例生存时间≥10 年的患者和 321 例 10 年内死亡的患者。

结果

中位总生存和无复发生存率分别为 5.5 年和 2.4 年。实际 10 年总生存率为 23.8%,实际 10 年无复发生存率为 8.1%。多因素分析显示,年龄>70 岁(OR 1.87,P=0.029)、丙型肝炎病毒阳性(OR 2.30,P=0.004)、Child-Pugh 分级 B(OR 3.28,P=0.003)和血小板计数<10×10 /µL(OR 1.93,P=0.033)是实际 10 年生存的独立危险因素。在 10 年随访期间,≥10 年生存者中有 66%发生了复发,其中 91%的患者接受了进一步的治愈性治疗,包括肝切除术或局部消融术治疗 HCC 复发。

结论

即使近 2/3的 10 年生存患者发生了复发,手术微波消融治疗 HCC 后 10 年的生存率仍可达到 24%左右。密切的术后随访和对复发的进一步治愈性治疗对于提高长期生存率很重要。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验